Clinical trial
Analysis of Circulating Tumor Markers in the Blood
Name
IC 2015-02
Description
Exploratory study on blood-borne biological markers and their correlation with clinical and pathological characteristics.
Trial arms
Trial start
2015-07-01
Estimated PCD
2024-09-01
Trial end
2025-09-01
Status
Active (not recruiting)
Treatment
Blood sampling
Up to 5 blood samplings can be performed at different time points
Arms:
Cohort 1 - "Anti checkpoint", Cohort 10 - "Palbociclib II", Cohort 11 - Sarcomas, Cohort 12 - Faslorad, Cohort 13 - MUm, Cohort 14 - CNBC Snipe, Cohort 15 - Breast CLI, Cohort 16 - Mum immunothérapie, Cohort 2 - "Oncoscan®", Cohort 3 - "CirCe-PLA", Cohort 4 - "CDX PDX", Cohort 5 - "Post-TP53", Cohort 6 - "Palbociclib", Cohort 7 - "CTC_PD-L1_Breast", Cohort 8 - "CTC_PD-L1_Broncho-Pulmonary", Cohort 9 - "NSCLC"
Tumor sampling
One tumor sampling can be performed, if applicable
Arms:
Cohort 14 - CNBC Snipe, Cohort 15 - Breast CLI, Cohort 3 - "CirCe-PLA", Cohort 4 - "CDX PDX", Cohort 9 - "NSCLC"
Stool sampling
Up to 5 blood samplings can be performed at different time points
Arms:
Cohort 9 - "NSCLC"
Size
682
Primary endpoint
Feasibility of the analysis of different blood-borne tumor biomarkers
18 months
Eligibility criteria
Inclusion Criteria:
1. Patient with any tumoral disease (proven or suspected), of any type and stage
2. More than18 years old
3. Signed informed consent form
Additional inclusion criteria if a tumor sample is needed:
4. Tumor considered as accessible by biopsy
5. Normal blood coagulation tests on the last blood analysis
Non-inclusion Criteria:
1. Patient in detention or protected by the law
2. Patient who cannot comply with the study follow up for geographical, social or psychological reasons
Additional non-inclusion criteria if a tumor sample is needed:
3. Anticoagulant or antiaggregant that cannot be interrupted for the biopsy
4. central-nervous system metastases only (unless a diagnostic or curative surgery is planned before the inclusion in the study)
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'DIAGNOSTIC', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 682, 'type': 'ACTUAL'}}
Updated at
2024-02-02
1 organization
Organization
Institut Curie